ClinicalTrials.gg
CompletedNCT03651128KarMMa-3Updated Jun 22, 2026

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

A Phase 3 interventional study of bb2121 and Daratumumab in Multiple Myeloma, sponsored by Celgene. Completed at 62 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
386
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
21st of 132
386 · median 50
Started
2019
with 22 others
Phase 3
24 of 132
4 open now
Registered
44th of 132
by date
Lead sponsor
3 of 132
Celgene

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 21st largest by enrollment, is one of 23 that started in 2019, is one of 24 in phase 3, and was the 44th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • bb2121
  • Relapsed and Refractory Multiple Myeloma
  • High Risk Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 18 years of age at the time of signing the form (ICF).
  2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements within this protocol and for a subject randomized to Treatment Arm A, subject agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.
  4. Subject has documented diagnosis of MM and , defined as:

    • M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP ≥ 0.5 g/dL or uPEP ≥ 200 mg/24 hours and/or
    • Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  5. Subject has received at least 2 but no greater than 4 prior MM regimens.
  6. Subject has received prior treatment with DARA, a proteasome inhibitor- and an immunomodulatory compound-containing regimen for at least 2 consecutive cycles.
  7. Subject must be to the last treatment regimen. Refractory is defined as documented progressive disease during or within 60 days (measured from the last dose of any drug within the regimen) of completing treatment with the last anti-myeloma regimen before study entry.
  8. Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.
  9. Subject has an (ECOG) performance status of 0 or 1.
  10. Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy.
  11. Adequate vascular access for leukapheresis
  12. Females of (FCBP) must:

    a. Have negative pregnancy test(s) as verified by the Investigator. This applies even if the subject practices true abstinence from heterosexual contact.

    b. Either practice true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of without interruption.

    c. Agree to abstain from breastfeeding during study participation. d. Refrain from tissue donation including egg cell donation or any other tissue/blood/organ donations.

  13. Male subjects must:

    a. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, even if he has undergone a successful vasectomy.

    b. Refrain from tissue donation including sperm or any other tissue/blood/organ donations.

  14. Only subjects that would be considered for any of the 5 proposed standard regimens (DPd, DVd, IRd, Kd, or EPd), as judged by the investigator, should be included in the study.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Subject has any condition that confounds the ability to interpret data from the study.
  4. Subject has nonsecretory multiple myeloma (MM).
  5. Subject has any of the following laboratory abnormalities:

    a. (ANC) \< 1,000/μL b. count: \< 75,000/μL in subjects in whom \< 50% of bone marrow nucleated cells are plasma cells and platelet count \< 50,000/μL in subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells (it is not permissible to transfuse a subject to reach this level) c. \< 8 g/dL (\< 4.9 mmol/L) (it is not permissible to transfuse a subject to reach this level) d. Serum (CrCl) \< 45 mL/min e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) f. Serum (AST) or alanine aminotransferase (ALT) > 2.5 × (ULN) g. Serum total > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome h. (INR) or activated partial thromboplastin time (aPTT) > 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)

  6. Subject has inadequate pulmonary function defined as oxygen saturation (SaO2) \< 92% on room air.
  7. Subject has prior history of , other than MM, unless the subject has been free of the disease for ≥ 5 years • Basal cell carcinoma of the skin

    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, [TNM] clinical staging system) or prostate cancer that can be treated with curative intent
  8. Subject has active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or amyloidosis.
  9. Subject with known central nervous system (CNS) involvement with myeloma.
  10. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation.
  11. Subject has known (COPD) with a (FEV1) 50% of predicted normal.
  12. Subject has a history or presence of CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
  13. Subject was treated with DARA in combination with POM with or without dex (DP±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DPd as bridging therapy but may receive DVd, IRd, Kd or EPdas bridging as per Investigator's discretion if randomized to Treatment Arm A.
  14. Subject was treated with DP±d as part of their most recent anti-myeloma treatment regimen, cannot receive DPd if randomized to Treatment Arm B but may receive DVd, IRd, Kd, or EPd as per Investigator's discretion.
  15. Subject was treated with DARA in combination with BTZ with or without dexamethasone (DV±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DVd as bridging therapy but may receive DPd, IRd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.
  16. Subject was treated with DV±d as part of their most recent anti-myeloma treatment regimen, cannot receive DVd if randomized to Treatment Arm B but may receive DPd, IRd, Kd, or EPd as per Investigator's discretion.
  17. Subject was treated with IXA in combination with LEN with or without dexamethasone (IR±d) as part of their most recent anti-myeloma treatment regimen, cannot receive IRd as bridging therapy but may receive DPd, DVd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.
  18. Subject was treated with IR±d as part of their most recent anti-myeloma treatment regimen, cannot receive IRd if randomized to Treatment Arm B but may receive DPd, DVd, Kd, or EPd as per Investigator's discretion.
  19. Previous history of an hematopoietic stem cell transplantation, treatment with any gene therapy-based therapeutic for cancer, cellular therapy for cancer or BCMA targeted therapy.
  20. Subject has received autologous stem cell transplantation (ASCT) within 12 weeks prior to randomization.
  21. Subject has received any of the following within the last 14 days prior to randomization:

    a. Plasmapheresis b. Major surgery (as defined by the Investigator) c. Radiation therapy other than local therapy for myeloma-associated bone lesions d. Use of any investigational agents and systemic anti-myeloma drug therapy

  22. Echocardiogram (ECHO) or multigated acquisition () with left ventricular ejection fraction (LVEF) \< 45%.
  23. Ongoing treatment with chronic (eg, cyclosporine or systemic at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed.
  24. Subject is positive for (HIV-1 and HIV-2), chronic or active or active hepatitis A or C.
  25. Subject has uncontrolled systemic fungal, bacterial, viral or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.
  26. Subject has a history of class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to randomization.
  27. to DARA, thalidomide, lenalidomide, POM, BTZ, IXA, CFZ, ELO or dexamathasone. This includes rash ≥ Grade 3 during prior thalidomide, POM or lenalidomide therapy.
  28. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab or hypersensitivity to the contained in the formulation of DARA, POM, LEN, IXA, BTZ, CFZ, ELO or dexamethasone.
  29. Subject is a female who is pregnant, nursing, or breastfeeding
  30. For a subject randomized to Treatment Arm B and will be on a POM- or LEN-containing regimen; unable or unwilling to undergo protocol required thromboembolism prophylaxis.

28 Subject is intolerant to bortezomib, or has acute diffuse infiltrative pulmonary and pericardial disease, subject cannot receive DVd as bridging therapy if randomized to Treatment Arm A or cannot receive DVd if randomized to Treatment Arm B.

31. Subject was treated with K±d as part of their most recent anti-myeloma treatment regimen, cannot receive Kd if randomized to Treatment Arm B but may receive DPd, DVd, IRd or EPd as per Investigator's discretion.

32. Subject was treated with EP±d as part of their most recent anti-myeloma treatment regimen, cannot receive EPd if randomized to Treatment Arm B but may receive DPd, DVd, Kd or IRd as per Investigator's discretion.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
386 participants (actual)

Study arms

  • Experimental
    Arm A - Administration of bb2121

    bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10\^6 CAR+ T cells after receiving lymphodepleting chemotherapy

    Biological: bb2121

  • Experimental
    Arm B- standard regimens as per Investigator's discretion

    The participants will receive one of following regimens dependent on the subject's most recent anti-myeloma treatment regimen: * Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd) OR * DARA in combination with bortezomib (BTZ) and low-dose dex (DVd) OR * Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd) OR * Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd) OR * Elotuzumab (ELO) in combination with POM and low-dose dexamethasone (EPd)

    Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Lenalidomide · Drug: Carfilzomib · Drug: Elotuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Time from randomization to the first documentation of progressive disease based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma assessed by an independent response committee (IRC) or death due to any cause, whichever occurs first.

    Time frame: Minimum of 5 years from randomization

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to time of death due to any cause

    Time frame: Minimum of 5 years from randomization

  2. Event-free Survival (EFS)

    Time from randomization to the first documentation of progressive disease, first day when subject receives another anti-myeloma treatment or death due to any cause, whichever occurs first

    Time frame: Minimum of 5 years from randomization

  3. Overall Response Rate (ORR)

    Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC

    Time frame: Minimum of 5 years from randomization

  4. Minimal Residual Disease (MRD)

    Percentage of MRD evaluable subjects that are MRD negative (defined at a minimum of 1 in 10\^5 nucleated cells) using flow cytometry (EuroFlow) and next generation sequencing (NGS)

    Time frame: Minimum of 5 years from randomization

  5. Complete Response (CR) Rate

    Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC

    Time frame: Minimum of 5 years from randomization

  6. Duration of Response (DOR)

    Time from first documentation of response (PR or better) to first documentation of disease progression or death from any cause, whichever occurs first

    Time frame: Minimum of 5 years from randomization

  7. Time to Response (TTR)

    TTR is calculated as the time from randomization to the initial documented response (PR or better) based on IMWG guideline for responders

    Time frame: Minimum of 5 years from randomization

  8. Adverse Events (AEs)

    Number of participants with adverse events

    Time frame: Minimum of 5 years from randomization

  9. Pharmacokinetics- Cmax

    Maximum peak in bb2121 chimeric antigen receptor (CAR) T cells

    Time frame: Minimum 5 years after bb2121 infusion

  10. Pharmacokinetics- tmax

    Time to peak of bb2121 CAR T cells

    Time frame: Minimum 5 years after bb2121 infusion

  11. Pharmacokinetics- AUC

    Area under the curve of CAR T cells

    Time frame: Minimum 5 years after bb2121 infusion

  12. Pharmacokinetics- t-last

    Time to last measurable CAR T cells

    Time frame: Minimum 5 years after bb2121 infusion

  13. Pharmacokinetics- AUC0-28days

    Area under the curve of CAR T cells from time zero to Day 28

    Time frame: Minimum 5 years after bb2121 infusion

  14. Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)

    Questionnaire will be used as a measure of health-related quality of life

    Time frame: Minimum of 5 years from randomization

  15. Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire

    Is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal

    Time frame: Minimum of 5 years from randomization

  16. Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20)

    Is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality

    Time frame: Minimum of 5 years from randomization

  17. Time to next antimyeloma treatment

    Time from randomization to first day when subject receives another anti-myeloma treatment

    Time frame: Minimum of 5 years from randomization

  18. Progression-free survival after next line therapy (PFS2)

    Time from randomization to second objective disease progression or death from any cause, whichever is first

    Time frame: Minimum of 5 years from randomization

07

Study locations

62 sites
  • Local Institution - 109
    Birmingham, Alabama 10016, United States
  • Local Institution - 141
    Scottsdale, Arizona 85259, United States
  • Local Institution - 145
    Los Angeles, California 90048, United States
  • Local Institution - 122
    Los Angeles, California 90095, United States
  • Local Institution - 124
    Palo Alto, California 94304, United States
  • Local Institution - 142
    Aurora, Colorado 80045, United States
  • Local Institution - 108
    Jacksonville, Florida 32224, United States
  • Local Institution - 102
    Tampa, Florida 33612, United States
  • Local Institution - 131
    Atlanta, Georgia 30322, United States
  • Local Institution - 140
    Atlanta, Georgia 30342, United States
  • Local Institution - 139
    Chicago, Illinois 60611, United States
  • Local Institution - 100
    Indianapolis, Indiana 46202-528, United States
  • Local Institution - 112
    Westwood, Kansas 66205-2003, United States
  • Local Institution - 104
    Baltimore, Maryland 21201-1595, United States
  • Local Institution - 134
    Boston, Massachusetts 02114, United States
  • Local Institution - 123
    Boston, Massachusetts 02215, United States
  • Local Institution - 120
    Ann Arbor, Michigan 48109-5936, United States
  • Local Institution - 125
    Rochester, Minnesota 55905-0001, United States
  • Local Institution - 114
    St Louis, Missouri 63110, United States
  • University Of Nebraska
    Omaha, Nebraska 68198-7680, United States
  • Local Institution - 138
    Hackensack, New Jersey 07601, United States
  • Local Institution - 119
    New York, New York 10029, United States
  • Local Institution - 115
    New York, New York 10065, United States
  • Local Institution - 135
    New York, New York 10065, United States
  • Local Institution - 113
    Durham, North Carolina 27705, United States
  • Local Institution - 111
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 110
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 101
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 106
    Nashville, Tennessee 37203, United States
  • Local Institution - 118
    Dallas, Texas 75246, United States
  • Local Institution - 103
    Dallas, Texas 75390, United States
  • Local Institution - 132
    Houston, Texas 77030, United States
  • Local Institution - 136
    Salt Lake City, Utah 84112, United States
  • Local Institution - 105
    Seattle, Washington 98104, United States
  • Local Institution - 107
    Madison, Wisconsin 53792, United States
  • Froedtert Hospital BMT Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution - 202
    Leuven, 3000, Belgium
  • Local Institution - 302
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution - 303
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 402
    Lille, 59037, France
  • Local Institution - 403
    Nantes, 44093, France
  • Local Institution - 400
    Paris, 75010, France
  • Local Institution - 401
    Toulouse, 31059, France
  • Local Institution - 515
    Cologne, 50937, Germany
  • Local Institution - 513
    Düsseldorf, 40225, Germany
  • Local Institution - 514
    Hamburg, 20246, Germany
  • Local Institution - 512
    Heidelberg, 69120, Germany
  • Local Institution - 511
    Würzburg, 97080, Germany
  • Local Institution - 611
    Bologna, 40138, Italy
  • Local Institution - 806
    Bunkyō City, 113-8677, Japan
  • Local Institution - 804
    Isehara City, Kanagawa, 259-1193, Japan
  • Local Institution - 807
    Nagoya, 467-8602, Japan
  • Local Institution - 805
    Shibuya-ku, 150-8935, Japan
  • Local Institution - 650
    Amsterdam, 1081 HV, Netherlands
  • Local Institution - 651
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 700
    Oslo, N-0027, Norway
  • Local Institution - 750
    Pamplona, 31008, Spain
  • Local Institution - 751
    Salamanca, 37007, Spain
  • Local Institution - 800
    Stockholm, SE-141 86, Sweden
  • Local Institution - 251
    Bern, 3010, Switzerland
  • Local Institution - 850
    Leeds, LS9 7TF, United Kingdom
  • Local Institution - 851
    London, SE5 9RS, United Kingdom
08

References and documents

Publications

  • Lopez-Munoz N, Bar N, Diels J, van Sanden S, Mendes J, Lee S, Hernando T, Lendvai N, Patel N, Ishida T, Er J, Harrison SJ. Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison. Adv Ther. 2026 Mar;43(3):1327-1340. doi: 10.1007/s12325-025-03479-y. Epub 2026 Feb 2. PubMed 41627370 ↗
  • Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon S, Abrahamsen IW, Baz R, Broijl A, Chen C, Jagannath S, Raje N, Scheid C, Delforge M, Benjamin R, Pabst T, Iida S, Berdeja J, Giralt S, Truppel-Hartmann A, Chen Y, Zhong X, Wu F, Piasecki J, Eliason L, Dhanda D, Felten J, Caia A, Cook M, Popa McKiver M, Rodriguez-Otero P. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024 Dec 5;144(23):2389-2401. doi: 10.1182/blood.2024024582. PubMed 39197072 ↗
  • Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20(18):1221-1235. doi: 10.2217/fon-2023-0954. Epub 2024 Apr 23. PubMed 38651976 ↗
  • Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10. PubMed 36762851 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2026, 83 months.

Of 108 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 83 months is above that.

Counting every sponsor, half of 180 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 29, 2018
StartActual
Apr 16, 2019
Primary completionActual
Apr 13, 2026
CompletionActual
Apr 13, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03651128
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 29, 2018
Start date
Apr 16, 2019
Primary completion
Apr 13, 2026
Completion
Apr 13, 2026
Last update
Jun 22, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Idecabtagene vicleucel · Daratumumab · Pomalidomide · Dexamethasone · Bortezomib · Ixazomib · Lenalidomide · Carfilzomib · Elotuzumab

Start the discussion